207 related articles for article (PubMed ID: 17704294)
1. Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion.
Elia C; Cassol E; Sidenius N; Blasi F; Castagna A; Poli G; Alfano M
J Leukoc Biol; 2007 Nov; 82(5):1212-20. PubMed ID: 17704294
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication.
Alfano M; Sidenius N; Panzeri B; Blasi F; Poli G
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8862-7. PubMed ID: 12084931
[TBL] [Abstract][Full Text] [Related]
3. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage.
Wohn KD; Kanse SM; Deutsch V; Schmidt T; Eldor A; Preissner KT
Thromb Haemost; 1997 Mar; 77(3):540-7. PubMed ID: 9066008
[TBL] [Abstract][Full Text] [Related]
4. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
5. Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1.
Kanse SM; Chavakis T; Al-Fakhri N; Hersemeyer K; Monard D; Preissner KT
J Cell Sci; 2004 Jan; 117(Pt 3):477-85. PubMed ID: 14679304
[TBL] [Abstract][Full Text] [Related]
6. Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.
Alfano M; Mariani SA; Elia C; Pardi R; Blasi F; Poli G
Blood; 2009 Feb; 113(8):1699-709. PubMed ID: 18941116
[TBL] [Abstract][Full Text] [Related]
7. The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection.
Alfano M; Sidenius N; Blasi F; Poli G
J Leukoc Biol; 2003 Nov; 74(5):750-6. PubMed ID: 12960238
[TBL] [Abstract][Full Text] [Related]
8. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 enhances human immunodeficiency virus type 1 expression in a chronically infected promonocytic cell line (U1) by a tumor necrosis factor alpha-independent mechanism.
Angel JB; Saget BM; Wang MZ; Wang A; Dinarello CA; Skolnik PR
J Interferon Cytokine Res; 1995 Jun; 15(6):575-84. PubMed ID: 7553227
[TBL] [Abstract][Full Text] [Related]
10. Extracellular high mobility group box-1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines.
Cassetta L; Fortunato O; Adduce L; Rizzi C; Hering J; Rovere-Querini P; Bianchi ME; Alfano M; Poli G
AIDS; 2009 Mar; 23(5):567-77. PubMed ID: 19194273
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells.
Ragno P; Montuori N; Covelli B; Hoyer-Hansen G; Rossi G
Cancer Res; 1998 Mar; 58(6):1315-9. PubMed ID: 9515821
[TBL] [Abstract][Full Text] [Related]
12. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
14. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P
J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290
[TBL] [Abstract][Full Text] [Related]
15. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
Gu JM; Johns A; Morser J; Dole WP; Greaves DR; Deng GG
J Cell Physiol; 2005 Jul; 204(1):73-82. PubMed ID: 15573379
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCĪµ.
Graziano F; Elia C; Laudanna C; Poli G; Alfano M
PLoS One; 2011; 6(8):e23674. PubMed ID: 21858203
[TBL] [Abstract][Full Text] [Related]
17. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.
Fuhrman B; Khateeb J; Shiner M; Nitzan O; Karry R; Volkova N; Aviram M
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1361-7. PubMed ID: 18436804
[TBL] [Abstract][Full Text] [Related]
18. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication.
Wada M; Wada NA; Shirono H; Taniguchi K; Tsuchie H; Koga J
Biochem Biophys Res Commun; 2001 Jun; 284(2):346-51. PubMed ID: 11394884
[TBL] [Abstract][Full Text] [Related]
19. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
Reuning U; Magdolen V; Hapke S; Schmitt M
Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
[TBL] [Abstract][Full Text] [Related]
20. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
